Research programme: brain injury therapies - PDS Biotechnology
Latest Information Update: 23 Oct 2022
At a glance
- Originator Edge Therapeutics
- Developer PDS Biotechnology Corporation; University of Toronto
- Class Anti-ischaemics; Dihydropyridines; Neuroprotectants; Nicotinic acids
- Mechanism of Action Calcium channel antagonists; Chymotrypsin inhibitors; Kallikrein inhibitors; Plasmin inhibitors; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries; Cerebral ischaemia; Neurological disorders; Subdural haematoma
Most Recent Events
- 06 Sep 2022 Discontinued - Preclinical for Cerebral ischaemia (Prevention) in USA (Intracerebral)
- 06 Sep 2022 Discontinued - Preclinical for Subdural haematoma (Prevention) in USA (Intracerebral)
- 06 Sep 2022 Discontinued for Brain injuries (Prevention) in North America (Intracerebral)